Halozyme Therapeutics
HALO
110.79
+1.07
+0.98%
Halozyme Therapeutics
US · HALO
#1276 by market cap
Listed 1970
110.79
+1.07
+0.98%
Live - 5344 symbols - heartbeat 199s ago
· 2026-10-08 07:31
Pre-market
111.00
+0.19%
After-hours
110.79
0.00%
Overnight
110.00
-0.71%
- Market cap
- 12.57B
- P/E (TTM)i
- 32.49
- P/Bi
- 87.58
- EPSi
- 2.56
- Div yieldi
- 0.00%
- 52W posi
- 89%
Reader sentiment
Are you bullish or bearish on HALO?
Anonymous reader poll. Unscientific, not investment advice.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
- Founded
- 1998
- CEO
- Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B.
- Employees
- 423
- Headquarters
- San Diego, California, United States of America
- Fiscal year end
- 12-31
- Website
- halozyme.com
Company profile
- Exchange
- US
- Symbol
- HALO
- Market-cap rank
- #1276
- Listing date
- 1970-01-01
- Market cap
- 12.57B
- Float cap
- 12.43B
- Shares out
- 113.50M
- Float shares
- 112.19M
Sectors & themes
Biotechnology
Best Growth Stocks
Fractional Shares JP
Quote time 2026-10-08 07:31:01 · For reference only, not investment advice and not tailored to your situation.